RxDoctor Payments Data

James Doran, MD

Family Medicine · Middletown, CTNPI 1942249610

Payments from drug & device makers

$634in general payments, 2019–2025

Across 37 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$156
  • Novo Nordisk$103
  • Pfizer$59
  • Lilly USA, LLC$54
  • Boehringer Ingelheim$52
  • Johnson & Johnson$36
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$634 in reported general payments places this provider in the 65th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$82,026
Medicare patients
155
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$59,185
JanuviaSitagliptin Phosphate37$50,655
EliquisApixaban65$46,298
OzempicSemaglutide22$31,026
FarxigaDapagliflozin Propanediol18$19,161
TradjentaLinagliptin22$17,630
Emgality PenGalcanezumab-Gnlm16$15,788
Breo ElliptaFluticasone/Vilanterol20$13,159
XareltoRivaroxaban15$13,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,394
LinzessLinaclotide15$7,703
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$6,003
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,138
Atorvastatin Calcium543$4,988
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$52$76,81580 claims
MerckJanuvia$11$50,65537 claims
PfizerEliquis, Dilantin$59$48,02277 claims
Novo NordiskOzempic$103$31,02622 claims
AstraZenecaFarxiga$28$19,16118 claims
Johnson & JohnsonXarelto$36$13,11015 claims
AbbVieLinzess, Synthroid$156$10,37246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →